-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – F-652 in Acute Liver Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - F-652 in Acute Liver Failure report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. F-652 in Acute Liver Failure Drug Details: F-652 is under...
-
Innovation Ranking
Innovation Ranking – F-star Therapeutics Inc
F-star Therapeutics Inc (F-star Therapeutics), formerly Spring Bank Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company. It discovers and develops novel class of therapeutics. The company develops nucleotide-based drugs and small molecule nucleic acid hybrids. Its development pipeline products include FS118, FS120, FS222, SB 11285, among other drug candidates. The company's drug products are used in the rescuing CPI treatment failures, improving outcomes in CPI naive, PD-L1 low tumors, chemotherapy outcomes, CPI outcomes, addressing unmet needs. Its partners programs include multiple...
-
Innovation Ranking
Innovation Ranking – F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories,...
-
Product Insights
Banyan Grp – Hokkaido Ballpark F Village Hotel Complex – Hokkaido
The Banyan Grp – Hokkaido Ballpark F Village Hotel Complex – Hokkaido involves the construction of 177 guest rooms, ranging from 20m2 to 150m2 in Kitahiroshima City, Hokkaido Prefecture, Japan. Equip yourself with the essential tools needed to make informed and profitable decisions with our Banyan Grp – Hokkaido Ballpark F Village Hotel Complex – Hokkaido report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days...
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Tominersen
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Tominersen report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Tiragolumab
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Tiragolumab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Prasinezumab
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Prasinezumab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Divarasib
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Divarasib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Vamikibart
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Vamikibart report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s Ruzotolimod
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's Ruzotolimod report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.